| Title |
|
Features and global impact of invasive fungal infections caused by Pneumocystis jirovecii: A systematic review to inform the World Health Organization fungal priority pathogens list |
|
|
| Publication Date |
|
| Author(s) |
|
| Type of document |
|
| Language |
|
| Entity Type |
|
| Publisher |
|
Oxford University Press (OUP) |
|
|
| Place of publication |
|
| DOI |
|
| UNE publication id |
|
| Abstract |
This systematic review evaluates the current global impact of invasive infections caused by Pneumocystis jirovecii (principally pneumonia: PJP), and was carried out to inform the World Health Organization Fungal Priority Pathogens List. PubMed and Web of Science were used to find studies reporting mortality, inpatient care, complications/sequelae, antifungal susceptibility/resistance, preventability, annual incidence, global distribution, and emergence in the past 10 years, published from January 2011 to February 2021. Reported mortality is highly variable, depending on the patient population: In studies of persons with HIV, mortality was reported at 5%–30%, while in studies of persons without HIV, mortality ranged from 4% to 76%. Risk factors for disease principally include immunosuppression from HIV, but other types of immunosuppression are increasingly recognised, including solid organ and haematopoietic stem cell transplantation, autoimmune and inflammatory disease, and chemotherapy for cancer. Although prophylaxis is available and generally effective, burdensome side effects may lead to discontinuation. After a period of decline associated with improvement in access to HIV treatment, new risk groups of immunosuppressed patients with PJP are increasingly identified, including solid organ transplant patients. |
|
|
| Link |
|
| Citation |
|
Medical Mycology, 62(6), p. 1-23 |
|
|
| ISSN |
|
| Start page |
|
| End page |
|
| Rights |
|
Attribution-NonCommercial 4.0 International |
|
|